title: [Newly development of phosphate binders in hyperphosphatemic patients with kidney dysfunction].
abstract: Hyperphosphatemia is the most common complication among patients with chronic kidney disease. Large scale observational studies have identified hyperphosphatemia as an independent risk factor for cardiovascular disease and mortality in hemodialysis patients. The combination therapy of dietary phosphate restriction and phosphate removal with dialysis treatment is still not enough to achieve the serum phosphate within the target. Thererfore, phosphate binders is necessary for many dialyzed patients with hyperphosphatemia. In this article, we will review the detail and development of phosphate binders and recommendation for clinical practice in hyperphosphatemia.
authors.affiliation: Division of Nephrology, Department of Internal Medicine, Wakayama Medical University, Japan.
authors.forename: Shigeo
authors.initials: S
authors.lastname: Negi
authors.forename: Shintaro
authors.initials: S
authors.lastname: Yamanaka
authors.forename: Daisuke
authors.initials: D
authors.lastname: Koreeda
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Yashiro
authors.forename: Takashi
authors.initials: T
authors.lastname: Shigematsu
mesh_terms: D002614:Chelating Agents / Q000627:therapeutic use; D006801:Humans; D054559:Hyperphosphatemia / Q000150:complications / Q000628:therapy*; D007668:Kidney / Q000378:metabolism / Q000503:physiopathology; D010710:Phosphates / Q000032:analysis / Q000737:chemistry / Q000378:metabolism*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000628:therapy*
chemical_list: D002614:Chelating Agents; D010710:Phosphates